Meta-analysis findings show that neoadjuvant imatinib achieves high 1-year, 3-year, and 5-year overall survival rates of 100%, 94%, and 88%, respectively. Patients with gastric and rectal tumors benefit most with an 8-month treatment duration. Additionally, mutational analysis can aid in treatment decision-making. Effective outcomes include an 89% R0 resection rate and a 67% disease response rate, highlighting the potential of neoadjuvant imatinib in locally advanced and metastatic gastrointestinal stromal tumors.
Review by Lam TJR, Udonwa SA (…) Goh BKP et 3 al. in World J Surg
© 2024 International Society of Surgery/Société Internationale de Chirurgie (ISS/SIC).